Shilpi Mehrotra
Senior Project Manager, Chemicals + Materials
Nutraceuticals have become the dominant force reshaping empty hard capsules (EHC) demand globally. In India, preventive health awareness, probiotics, botanicals, and immunity boosting supplements are accelerating capsule consumption much faster than traditional pharmaceuticals. Markets of Australia and New Zealand show a similar pattern, where growth stems from complementary medicines and practitioner-led supplement channels compared to that from high-volume prescription drugs. Europe and Brazil echo this trajectory, with premium over-the-counter (OTC) and clean label nutraceuticals increasingly favoring advanced capsule formats. This pattern illustrates a global pivot—growth in empty hard capsules is now driven more by nutraceuticals than pharmaceuticals, with lifestyle wellness leading the way.
HPMC Capsules Adoption Grows, But Selectively and Unevenly
HPMC capsules continue to gain global traction with their vegetarian, vegan, allergen-free, and clean-label positioning. However, adoption varies significantly by region based on cost, machinability, and supply dynamics. India and ANZ demonstrate strong demand but increasingly selective uptake, as many high-speed Contract manufacturing organizations (CMOs) still prefer gelatin capsules. In Brazil, while gelatin capsules hold the lead in cost–sensitive generics, HPMC capsules remain a minority but are rising in nutraceuticals and premium OTC segments where differentiation matters. Europe has been a frontrunner in differentiation through innovation in capsules, with high adoption of gelling agent free HPMC capsules heavily inclining toward clean-label trends. Lately, Europe is observed to be reversing course: manufacturers are returning to traditional HPMC capsules with gelling agents, mainly for machinability and cost efficiency. HPMC capsules are growing globally, but they will not fully replace gelatin capsules because practical factors such as cost, machine performance, and supply still drive decisions. In specialty applications of nutraceuticals, pullulan capsules are also making quick in-roads.
Functional and Modified-Release Capsules Accelerate Globally
Across regions, the fastest-growing functional category is modified-release and targeted delivery capsules. In India, controlled release capsules are increasingly used in chronic therapies such as anti-diabetic and gastrointestinal treatments, while nutraceuticals adopt enteric and targeted-delivery formats for probiotics and enzymes. Europe reflects the same trend, with modified-release technologies becoming essential for probiotic efficacy and consumer experience. ANZ, though slower in adoption, is experiencing rising demand for delayed release and acid– resistant capsules, especially for export-bound nutraceutical products. Even in Brazil, use cases are expanding for moisture sensitive or hygroscopic actives that benefit from HPMC-based functional technologies. This global movement signals a maturing consumer and healthcare market that values not only ingredients but also how they are delivered.
Supply Reliability, Localization, and CDMO Partnerships Reshape the Ecosystem
Global capsule buyers increasingly prioritize supply assurance, regulatory compliance, and partnership depth. Brazil illustrates this dramatically with a strategic shift from imports to local capacity expansion, supported by inventory buffers, regional distributor partnerships, and stronger QA capabilities. In India, the evolution of CMOs into end-to-end CDMOs is reshaping customer expectations. Nutraceutical and Ayurveda brands are outsourcing to partners that can deliver R&D support and regulatory documentation, in addition to specialized capsule technologies. Capsule buyers in ANZ similarly are inclined toward capsule suppliers and CMOs that offer consistent quality, audit readiness, and long-term reliability. Global EHC supply chain is becoming more integrated, more compliant, and more partnership-driven than ever before.
Cost Pressures, Competitive Pricing, and Market Volatility Influence Purchasing
Pricing dynamics are increasingly shaping strategic decisions for capsule buyers worldwide. European markets see historically low EHC prices since the last two years due to fierce competition from Asian suppliers—pressuring margins, particularly for HPMC producers. India sees stable gelatin capsules pricing contrasted, with rising HPMC capsules costs driven by raw materials and processing complexity. Brazil contends with structural volatility, including gelatin capsules price swings linked to collagen supply and foreign exchange fluctuations (USD/BRL). In ANZ, HPMC capsules prices remain elevated due to import dependency and limited supplier overlap, while gelatin capsules experience only modest inflation. These pressures are driving smarter procurement behaviors globally, from Brazil’s dual portfolio strategy to Europe’s shift toward cost-efficient HPMC variants.
Find out more with our latest report, Empty Hard Capsules, 2026: Market Analysis and Opportunities, which provides a comprehensive analysis of the market for empty hard capsules for pharmaceuticals and nutraceuticals. The analysis base year is 2025, with forecasts to 2030 covering all types of capsules with a deep dive into the market by functionality and customer type. The regions covered include Australia, India, New Zealand and Brazil, complementing recent reports focused on North America and Europe.
